Related Experiment Video

Updated: Feb 28, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K

Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in

Hanghang Wang1, Patrick H Pun2, Lydia Kwee1

  • 1Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA.

Cardiorenal Medicine
|June 15, 2017
PubMed

Insights

APOL1 genetic variants are linked to chronic kidney disease (CKD) but not cardiovascular disease (CVD) in African-Americans. Age, diabetes, and ejection fraction predict CKD in APOL1 homozygotes.

Area of Science:

  • Genetics and Cardiovascular Health
  • Nephrology and Epidemiology

Background:

  • The association between APOL1 genetic variants and chronic kidney disease (CKD) is well-established.
  • However, the link between APOL1 variants and cardiovascular disease (CVD) remains unclear.
  • This study investigated the CKD and cardiovascular risk associated with APOL1 variants in a population undergoing secondary cardiovascular prevention.

Purpose of the Study:

  • To determine the association between APOL1 risk variants and prevalent/incident CKD, coronary artery disease (CAD), and incident CVD events.
  • To explore the role of APOL1 variants in cardiovascular and kidney disease risk within a secondary prevention cohort.

Main Methods:

  • Genotyping of two APOL1 risk variants in 1,641 African-Americans from the CATHGEN biorepository.
  • Categorization into noncarriers, heterozygote, and homozygote carriers of APOL1 risk alleles.
  • Statistical analysis using logistic regression and Cox proportional hazards models, adjusted for CVD risk factors.

Main Results:

  • Confirmed association between APOL1 variants and prevalent CKD (OR: 1.85).
  • No significant associations found between APOL1 variants and incident CKD, prevalent CAD, incident CVD events, or mortality.
  • In APOL1 homozygous individuals, age, type 2 diabetes, and ejection fraction predicted incident CKD risk.

Conclusions:

  • APOL1 genetic variants are not associated with coronary artery disease or incident cardiovascular events in this cohort.
  • Age, type 2 diabetes, and baseline ejection fraction are key predictors of subsequent CKD in individuals with homozygous APOL1 status.
Abstract

Keywords:
Apolipoprotein L1Cardiovascular diseaseChronic kidney diseaseGene polymorphismPopulation genetics

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.9K
Application of Laser Microdissection to Uncover Regional Transcriptomics in Human Kidney Tissue05:46

Application of Laser Microdissection to Uncover Regional Transcriptomics in Human Kidney Tissue

Published on: June 9, 2020

4.4K

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
863
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
801
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
529
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
391
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
79